Northbrook, IL -- (SBWIRE) -- 09/29/2020 -- According to the new market research report "Amniotic Products Market by Type [Amniotic Membranes (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Amniotic Suspensions], Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital, ASCs) – Global Forecast to 2025? published by MarketsandMarkets™.

The Global Amniotic Products Market is projected to reach USD 1,095 million by 2025 from USD 748 million in 2020, at a CAGR of 7.9%

Recent Developments in Industry;

- In 2019, Smith & Nephew acquired Osiris Therapeutics, complementing the company's advanced wound management unit by offering regenerative medicine products inclusive of skin, bone graft, and articular cartilage substitutes.

- In 2018, the US FDA granted the Regenerative Medicine Advanced Therapy (RMAT) designation to MiMedx's AmnioFix Injectable for use in the treatment of osteoarthritis (OA) of the knee.

- In 2017, Organogenesis acquired NuTech to support the firm's development of next-generation amniotic products. The newly-combined company offers a portfolio of advanced next-generation products for the wound care and surgical biologics markets.

Browse 101 market data tables and 29 figures spread through 126 pages and in-depth TOC | Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=191575976

The amniotic membranes segment is expected to grow at the highest CAGR during the forecast period.

On the basis of type, categorized into two segments, amniotic membranes and amniotic suspensions. The amniotic membranes segment accounted for the largest share of the amniotic products market in 2019. It is also projected to record the highest CAGR during the forecast period. Amniotic membranes have anti-inflammatory, anti-angiogenic, anti-fibrotic, and anti-microbial properties. These benefits of amniotic membranes support their adoption. This is a major factor driving market growth.

Hospitals & ASCs are the largest end users of amniotic products.

Based on end user, segmented into hospitals & ASCs and other end users. In 2019, hospitals & ASCs accounted for the largest share of the amniotic membranes market. Factors such as the high demand for wound care biologics (including amniotic tissue products) in hospitals and ASCs, the high patient inflow in this care setting, and the availability of reimbursements are driving the growth of this segment.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=191575976

The global amniotic products market has been divided into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global amniotic membranes market in 2019. This can be attributed to the high prevalence of target diseases, increasing geriatric population, rising awareness about advanced treatment options, and the strong presence of key market players of amniotic products. The presence of a well-established healthcare system and ongoing investments by hospitals to upgrade & expand their operating capabilities are other factors supporting market growth in North America.

The prominent players operating in amniotic membranes market include MiMedx (US), Smith & Nephew (UK), Organogenesis (US), and Integra LifeSciences Corporation (US). Other players include Stryker Corporation (US), Wright Medical (Netherlands), Applied Biologics (US), Celularity (US), Katena Products (US), Lucina BioSciences (US), Next Biosciences (South Africa), Skye Biologics (US), Surgenex (US), TissueTech (US), Ventris Medical (US), StimLabs (US), VIVEX Biologics (US), LifeCell International (India), NuVision Biotherapies (England), and Genesis Biologics (US).